Table 1.
Main published series including Kaposi’s sarcoma in HIV-patients with suppressed viremia.
| Reference | Country | Number of Subjects | HIV-RNA Value Restrictions for Cases to Be Included | CD4 Count Restrictions for Cases to Be Included | Median CD4 Count | Median CD4 Nadir | cART Conditions to Be Included | Median Duration on cART | Types of cART |
|---|---|---|---|---|---|---|---|---|---|
| [5] | USA | 9 | <300 copies/mL for at least 2 years | ≥300/mm3 | - | 340/mm3 (range: 90–455) | - | 7 years (range: <1–19) | PI-based or NNRTI-based therapy |
| [6] | USA | 20 | <75 c opies/mL |
≥300/mm3 | 483/mm3 (range: 300–625) | 216/mm3 (range: 4–431) | - | 5 years (range: 1–12) | PI-based (n = 11, 55%) or NNRTI-based (n = 9, 45%) therapy |
| [7] | France | 21 | <50 copies/mL | - | 449/mm3 (IQR: 241–625) | 196/mm3 (IQR: 84–329) | ≥12 months | - | PI-based (n = 4, 19%) or NNRTI-based (n = 7, 33%) or INSTI-based (n = 10, 48%) therapy |
| [8] | France | 12 | <50 copies/mL for at least 12 months | - | 723/mm3 (range: 520–881) | - | - | - | - |
PI, protease inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. INSTI, integrase stand transfer inhibitor.